Please use this identifier to cite or link to this item:
https://ir.swu.ac.th/jspui/handle/123456789/14458
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yingsakmongkol N. | |
dc.contributor.author | Maraprygsavan P. | |
dc.contributor.author | Sukosit P. | |
dc.date.accessioned | 2021-04-05T03:34:54Z | - |
dc.date.available | 2021-04-05T03:34:54Z | - |
dc.date.issued | 2011 | |
dc.identifier.issn | 10672516 | |
dc.identifier.other | 2-s2.0-80054957456 | |
dc.identifier.uri | https://ir.swu.ac.th/jspui/handle/123456789/14458 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-80054957456&doi=10.1053%2fj.jfas.2011.05.006&partnerID=40&md5=40369c9bdddb6484e3f9a05505e60c82 | |
dc.description.abstract | This randomized controlled trial was undertaken to evaluate the effect of WF10 (Immunokine) as an adjunct to the standard treatment of diabetic foot ulcer. A total of 40 participants were randomized into 2 groups of 20. One group underwent standard therapy combined with infusions of WF10, and 1 underwent standard therapy combined with placebo. The wound severity scores, which vary with the severity of infection and inflammation, necrotic and granulation tissues, and wound depth and area, were assessed weekly for 9 weeks. Before treatment, the wound severity scores were not significantly different statistically between the 2 groups (13.7 ± 2.8 and 12.9 ± 3.2). After 9 weeks, the WF10 group had a statistically significant decreased wound severity score compared with that of the placebo group (1.8 ± 1.9 versus 4.4 ± 5.3, respectively, p < .05). Subgroup analyses comparing the WF10 and placebo groups showed statistically significant decreases of infection and inflammation (0.0 ± 0.0 versus 0.8 ± 0.9, respectively, p < .01), necrotic tissue (0.0 ± 0.0 versus 0.8 ± 1.1, respectively, p < .01), and an increase of the amount of granulation tissue (0.1 ± 0.3 versus 0.8 ± 1.2, respectively, p < .05). The wound depth and wound area also decreased more in the WF10 group; however, these decreases were not statistically significant. No severe adverse events were observed throughout the observation period. We concluded that the addition of WF10 to standard wound care statistically significantly reduced the wound severity score, infection and inflammation, and necrotic tissue and enhanced the formation of granulation tissue. © 2011 American College of Foot and Ankle Surgeons. | |
dc.subject | immunokine | |
dc.subject | placebo | |
dc.subject | tetrachlorodecaoxide | |
dc.subject | unclassified drug | |
dc.subject | adjuvant therapy | |
dc.subject | adult | |
dc.subject | article | |
dc.subject | clinical article | |
dc.subject | controlled study | |
dc.subject | diabetic foot | |
dc.subject | disease severity | |
dc.subject | double blind procedure | |
dc.subject | drug efficacy | |
dc.subject | drug safety | |
dc.subject | female | |
dc.subject | granulation tissue | |
dc.subject | human | |
dc.subject | male | |
dc.subject | multiple cycle treatment | |
dc.subject | randomized controlled trial | |
dc.subject | side effect | |
dc.subject | skin inflammation | |
dc.subject | skin necrosis | |
dc.subject | thrombophlebitis | |
dc.subject | treatment outcome | |
dc.subject | wound assessment | |
dc.subject | wound infection | |
dc.subject | Aged | |
dc.subject | Chlorine | |
dc.subject | Combined Modality Therapy | |
dc.subject | Debridement | |
dc.subject | Diabetic Foot | |
dc.subject | Dose-Response Relationship, Drug | |
dc.subject | Double-Blind Method | |
dc.subject | Drug Administration Schedule | |
dc.subject | Female | |
dc.subject | Follow-Up Studies | |
dc.subject | Granulation Tissue | |
dc.subject | Humans | |
dc.subject | Infusions, Intravenous | |
dc.subject | Male | |
dc.subject | Middle Aged | |
dc.subject | Oxides | |
dc.subject | Reference Values | |
dc.subject | Severity of Illness Index | |
dc.subject | Skin Care | |
dc.subject | Treatment Outcome | |
dc.subject | Wound Healing | |
dc.title | Effect of WF10 (Immunokine) on Diabetic Foot Ulcer Therapy: A Double-blind, Randomized, Placebo-controlled Trial | |
dc.type | Article | |
dc.rights.holder | Scopus | |
dc.identifier.bibliograpycitation | Journal of Foot and Ankle Surgery. Vol 50, No.6 (2011), p.635-640 | |
dc.identifier.doi | 10.1053/j.jfas.2011.05.006 | |
Appears in Collections: | Scopus 1983-2021 |
Files in This Item:
There are no files associated with this item.
Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.